<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02036086</url>
  </required_header>
  <id_info>
    <org_study_id>ML28606</org_study_id>
    <nct_id>NCT02036086</nct_id>
  </id_info>
  <brief_title>Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases</brief_title>
  <official_title>A Pilot Study of the Neo-adjuvant Use of Vemurafenib Plus Cobimetinib (GDC-0973) in Patients With BRAF Mutant Melanoma With Palpable Lymph Node Metastases.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the clinical and pathological response to vemurafenib and
      cobimetinib in the neoadjuvant treatment of patients with histologically confirmed, BRAF V600
      mutation-positive Stage IIIB and C melanoma. 20 patients will be treated with vemurafenib and
      cobimetinib for 2 months. Then they will be assessed for surgery. Patients will undergo
      surgery and subsequently resume taking vemurafenib and cobimetinib after recovery from
      surgery. Patients will undergo radiation therapy if appropriate then continue vemurafenib and
      cobimetinib. The maximum treatment period is 12 months. After 12 months of treatment,
      patients will be followed for disease recurrence and survival during for a total of 5 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At Screening: Assessments will include CT or MRI of the brain, CT of chest, abdomen and
      pelvis, dermatology assessment, head and neck exam, pelvic and anal exam, ophthalmology exam,
      electrocardiogram (ECG), echocardiogram (ECHO) or multigated acquisition (MUGA) scan, a
      history and physical exam. A core biopsy will be performed within 14 days of study entry.

      During Treatment: The maximum treatment period is 12 months. Patients will be assessed
      monthly while on treatment. Assessments performed will include vital signs assessment and
      physical exam, dermatology exam, ophthalmology exam, echocardiogram (ECHO) or multigated
      acquisition (MUGA) scan, electrocardiogram (ECG), safety blood tests, pelvic and anal exam.

      Follow-up after treatment: Patients will be followed for 5 years. Radiology exams will be
      done to assess for disease. Other assessments performed include vital signs assessment and
      physical exam, dermatology exam, include echogram (ECHO) or multigated acquisition (MUGA)
      scans.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The feasibility of treating patients with unresectable melanoma and palpable lymph node metastases that harbor the BRAF mutation with neoadjuvant vemurafenib.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resectability rates post vemurafenib therapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local-regional recurrence rates after treatment with neo-adjuvant vemurafenib.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to distant metastases and Distant Metastatic Free Survival (DMFS).</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS) and Overall Survival (OS).</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunohistochemical correlates of tumor response.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of vemurafenib in the neoadjuvant setting</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Vemurafenib, pill, twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vemurafenib, 960 mg, oral, twice daily plus Cobimetinib, 60 mg, oral, four times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib</intervention_name>
    <description>Drug</description>
    <arm_group_label>Vemurafenib, pill, twice daily</arm_group_label>
    <other_name>Zelboraf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>Drug</description>
    <arm_group_label>Vemurafenib, pill, twice daily</arm_group_label>
    <other_name>GDC-0973</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Naïve to treatment for locally advanced unresectable disease (Stage IIIB and C). Prior
             adjuvant therapy (including immunotherapy, e.g., Ipilimumab) is allowed if prior to
             nodal recurrence.

          2. Biopsy proven unresected melanoma with palpable regional lymph node metastases, stage
             IIIB or C or with recurrent regional lymphadenopathy that are not suitable or not
             preferred for surgical intervention.

          3. BRAFV600 mutation positive

          4. Eastern Cooperative Oncology Group performance status of 0 or 1

          5. Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

          6. Adequate hematologic, renal and liver function within 7 days prior to the first dose
             of vemurafenib.

          7. Agree to always use an effective form(s) of contraception beginning from the informed
             consent signature date until at least 6 months after completion of study therapy

          8. Negative serum pregnancy test within 14 days prior to start of treatment in women of
             childbearing potential only.

        Exclusion Criteria:

          1. Cannot have received any prior therapy. Previous adjuvant immunotherapy is allowed if
             more than 3 months have elapsed prior to nodal recurrence.

          2. History of prior RAF or MEK pathway inhibitor treatment.

          3. Active malignancy (other than BRAF−mutated melanoma) or a previous malignancy within
             the past 3 years are excluded; except for patients with resected melanoma, resected
             basal cell carcinoma (BCC), resected cutaneous squamous cell carcinoma (SCC), resected
             melanoma in situ, resected carcinoma in-situ of the cervix, and resected carcinoma
             in-situ of the breast.

          4. Evidence of distant metastatic disease.

          5. History of clinically significant liver disease (including cirrhosis), current alcohol
             abuse, or known infection with Human Immunodeficiency Virus (HIV), hepatitis B virus,
             or hepatitis C virus.

          6. Active infection or chronic infection requiring chronic suppressive antibiotics

          7. Pregnant or breastfeeding

          8. Active autoimmune disease

          9. Acromegaly

         10. History of malabsorption or other clinically significant metabolic dysfunction

         11. Requires a concomitant medication or dietary supplement that is prohibited during the
             study

         12. Current, recent (within 28 days of enrolment) or planned use of any investigational
             product outside of this study

         13. The following foods or supplements are prohibited at least 7 days prior to initiation
             of and during study treatment:

               1. St. John's wort or hyperforin

               2. Grapefruit juice

         14. History of or evidence of retinal pathology on ophthalmologic examination that is
             considered a risk factor for neurosensory retinal detachment / central serous
             chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular
             degeneration.

         15. Risk factors for retinal vein occlusion (RVO) based on the following:

               1. Uncontrolled glaucoma with intra-ocular pressures

               2. Serum cholesterol ≥Grade 2

               3. Hypertriglyceridemia ≥Grade 2

               4. Hyperglycemia (fasting) ≥Grade 2

         16. Clinically significant cardiac dysfunction, including the following:

               1. Current unstable angina

               2. Current symptomatic congestive heart failure of New York Heart Association class
                  2 or higher

               3. History of congenital long QT syndrome or or corrected QT interval greater than
                  450 msec at baseline or uncorrectable abnormalities in serum electrolytes
                  (sodium, potassium, calcium, magnesium, phosphorus).

               4. Current uncontrolled hypertension ≥Grade 2 (patients with a history of
                  hypertension controlled with anti-hypertensives to ≤ Grade 1 are eligible).

               5. Left ventricular ejection fraction (LVEF) below institutional lower limit of
                  normal (LLN) or below 50%, whichever is lower

         17. Palliative radiotherapy or major surgery within 14 days prior to first dose of study
             treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teresa Petrella, MD, BSc, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teresa Petrella, MD, BSc, MSc</last_name>
    <phone>416 480 5248</phone>
    <email>teresa.petrella@sunnybrook.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frances Wright, MD, MEd</last_name>
    <phone>416 480 4210</phone>
    <email>frances.wright@sunnybrook.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Ottawa Hospital - General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Nessim, MD, MSc</last_name>
      <phone>613-737-8899</phone>
      <phone_ext>71085</phone_ext>
      <email>cnessim@toh.on.ca</email>
    </contact>
    <investigator>
      <last_name>Carolyn Nessim, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Petrella, MD, BSc, MSc</last_name>
      <phone>416 480 5248</phone>
      <email>teresa.petrella@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Teresa Petrella, MD, BSc, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catalin Mihalcioiu, MD</last_name>
      <phone>514 934 1934</phone>
      <phone_ext>35800</phone_ext>
      <email>catalin.mihalcioiu@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Catalin Mihalcioiu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001 Aug 15;19(16):3622-34.</citation>
    <PMID>11504744</PMID>
  </reference>
  <reference>
    <citation>Bevilacqua RG, Coit DG, Rogatko A, Younes RN, Brennan MF. Axillary dissection in melanoma. Prognostic variables in node-positive patients. Ann Surg. 1990 Aug;212(2):125-31.</citation>
    <PMID>2375645</PMID>
  </reference>
  <reference>
    <citation>Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010 Apr 7;102(7):493-501. doi: 10.1093/jnci/djq009. Epub 2010 Feb 23. Review.</citation>
    <PMID>20179267</PMID>
  </reference>
  <reference>
    <citation>Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dréno B, Kirkwood JM. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer. 2008 Mar 1;112(5):982-94. doi: 10.1002/cncr.23251. Review.</citation>
    <PMID>18236459</PMID>
  </reference>
  <reference>
    <citation>Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009 Dec 20;27(36):6199-206. doi: 10.1200/JCO.2009.23.4799. Epub 2009 Nov 16.</citation>
    <PMID>19917835</PMID>
  </reference>
  <reference>
    <citation>Shah GD, Socci ND, Gold JS, Wolchok JD, Carvajal RD, Panageas KS, Viale A, Brady MS, Coit DG, Chapman PB. Phase II trial of neoadjuvant temozolomide in resectable melanoma patients. Ann Oncol. 2010 Aug;21(8):1718-22. doi: 10.1093/annonc/mdp593. Epub 2010 Jan 15.</citation>
    <PMID>20080829</PMID>
  </reference>
  <reference>
    <citation>Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, Kirkwood JM. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol. 2006 Jul 1;24(19):3164-71.</citation>
    <PMID>16809739</PMID>
  </reference>
  <reference>
    <citation>Gibbs P, Anderson C, Pearlman N, LaClaire S, Becker M, Gatlin K, O'Driscoll M, Stephens J, Gonzalez R. A phase II study of neoadjuvant biochemotherapy for stage III melanoma. Cancer. 2002 Jan 15;94(2):470-6.</citation>
    <PMID>11900232</PMID>
  </reference>
  <reference>
    <citation>Young K, Minchom A, Larkin J. BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation. Future Oncol. 2012 May;8(5):499-507. doi: 10.2217/fon.12.43.</citation>
    <PMID>22646765</PMID>
  </reference>
  <reference>
    <citation>Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011 Apr 1;29(10):1239-46. doi: 10.1200/JCO.2010.32.4327. Epub 2011 Feb 22.</citation>
    <PMID>21343559</PMID>
  </reference>
  <reference>
    <citation>Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012 Feb 23;366(8):707-14. doi: 10.1056/NEJMoa1112302.</citation>
    <PMID>22356324</PMID>
  </reference>
  <reference>
    <citation>Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 Jun 30;364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5.</citation>
    <PMID>21639808</PMID>
  </reference>
  <reference>
    <citation>Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010 Dec 16;468(7326):973-7. doi: 10.1038/nature09626. Epub 2010 Nov 24.</citation>
    <PMID>21107323</PMID>
  </reference>
  <reference>
    <citation>Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4.</citation>
    <PMID>22663011</PMID>
  </reference>
  <reference>
    <citation>Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014 Nov 13;371(20):1867-76. doi: 10.1056/NEJMoa1408868. Epub 2014 Sep 29.</citation>
    <PMID>25265494</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2013</study_first_submitted>
  <study_first_submitted_qc>January 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2014</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanoma stage IIIB or C with BRAF mutation</keyword>
  <keyword>Recurrent regional lymphadenopathy not suitable for surgery</keyword>
  <keyword>Eligible for neoadjuvant vemurafenib and cobimetinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vemurafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

